NASDAQ
Action plan following warning letter has been validated by FDA
PARIS, July 15, 2016 (GLOBE NEWSWIRE) -- AB Science SA (NYSE Euronext - FR0010557264 ...
GSK Exclusively Licenses Intellectual Property for Respiratory Disease Target Identified Using Five Prime’s Proprietary Protein Discovery Platform
SOUTH SAN FRANCISCO, Calif., July 14, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. ...
Investigator-Sponsored Phase 2 Study Results Show pSivida’s Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve
WATERTOWN, Mass., July 14, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader ...
Action plan following warning letter has been validated by FDA
Paris, France, July 14, 2016 (GLOBE NEWSWIRE) -- AB Science SA (NYSE Euronext - ...
Surgical Care Affiliates Partners With Raritan Valley Surgery Center
DEERFIELD, Ill., July 14, 2016 (GLOBE NEWSWIRE) -- Surgical Care Affiliates, Inc. (NASDAQ:SCAI) (“SCA”), ...
Argos Therapeutics Announces First Patient Dosed in Stage 2 of Adult Eradication Trial of AGS-004 in the Treatment of HIV
The investigator-initiated Phase 2 trial is designed to evaluate the virologic impact of the ...
Argos Therapeutics Announces First Patient Dosed in Stage 2 of Adult Eradication Trial of AGS-004 in the Treatment of HIV
The investigator-initiated Phase 2 trial is designed to evaluate the virologic impact of the ...
RECORDATI ACQUIRES THE SWISS PHARMACEUTICAL COMPANY PRO FARMA
MILAN, Italy, July 14, 2016 (GLOBE NEWSWIRE) -- Recordati announces the acquisition of 100% ...
Trinity Biotech plc to Announce Second Quarter Fiscal Year 2016 Financial Results
DUBLIN, Ireland, July 14, 2016 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading ...
Trinity Biotech plc to Announce Second Quarter Fiscal Year 2016 Financial Results
DUBLIN, Ireland, July 14, 2016 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading ...
100,000 Orion Corporation A shares converted into B shares
ORION CORPORATION STOCK EXCHANGE RELEASE 14 JULY 2016 at 9.00 a.m. EEST ...
CELYAD S.A.: Celyad successfully completes safety follow-up of the first patient at the fourth dose level in the NKR-2 Phase I trial
No safety issues or dose limiting toxicity reported in the first patient at the ...
Galena Biopharma Announces Closing of Registered Direct Offering
SAN RAMON, Calif., July 13, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a ...
